Huadong's China Phase 3 Roflumilast Cream Completes; No Results Posted Yet
The trial closed against a vehicle comparator with a primary endpoint that already cleared bar twice for Arcutis in the US, but Huadong has not disclosed a topline result.
Executive Summary
- NCT06648772 moved to Completed status on the registry on 2026-07-06, with enrollment finalized at 190 patients, but no topline efficacy or safety data has been posted NCT06648772Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 StudyNCT06648772.
- The primary endpoint, IGA treatment success at week 8 against a vehicle cream, is the same construct that met significance in Arcutis' two US pivotal trials, DERMIS-1 (42.4% vs 6.1%, P<0.0001) and DERMIS-2 (37.5% vs 6.9%, P<0.0001), which sets a specific bar for comparison once China data appears.
- The AppliedXL clinical-significance read of 20.4%, computed in October 2024 before any data existed, rests on structural features like single-country design and endpoint-type-phase base rates rather than the drug's own trial history, so it should not be read as a forecast of this trial's result [AXL-MODEL].
- The absence of a posted result nine months after the stated primary completion date is the operative fact for investors tracking Huadong's China psoriasis program, not the completion event itself.
What changed
The ClinicalTrials.gov registry for NCT06648772 updated on 2026-07-06 to show the 190-patient trial as Completed, with enrollment finalized at 190 from a prior anticipated count of 189 NCT06648772Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 StudyNCT06648772. The trial's title identifies it as a randomized, double-blind, vehicle-controlled study of Roflumilast Cream 0.3% (branded ZORYVE in the US) in patients aged 6 and older with plaque psoriasis. No results have been posted on ClinicalTrials.gov, and the registry explicitly confirms this: "No results posted on ClinicalTrials.gov". The primary completion date is listed as 2025-10-13, itself a slip from an earlier target of 2025-06-28 NCT06648772Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 StudyNCT06648772.
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the endpoint measures
The single primary endpoint is the proportion of subjects achieving IGA treatment success after 8 weeks, defined as an IGA score of 0 or 1 with at least a 2-point improvement from baseline. This is not a novel endpoint construct for roflumilast cream. Arcutis Biotherapeutics ran the same measure in two US Phase 3 trials, DERMIS-1 and DERMIS-2, both of which met the endpoint with wide separation from vehicle: 42.4% versus 6.1% in DERMIS-1 and 37.5% versus 6.9% in DERMIS-2, both at P<0.0001. Those results supported FDA approval of ZORYVE cream under NDA215985. The mechanism and endpoint are proven in a US population; what remains unproven is replication in a Chinese cohort of 190 patients.
The model read
The only probability figure carried in the seed for this catalyst is a clinical-significance read of 20.4%, generated on 2024-10-17, before the trial had any data [AXL-MODEL]. That figure is not an endpoint-met probability and should not be read as one. It sits alongside separate structural reads of 96.6% for trial completion, 91.4% for endpoint-met likelihood, and 96.0% for regulatory approval, all computed at the same pre-data timestamp [AXL-MODEL]. The clinical-significance driver mix leans on operational-design features, single-country trial status, one regulatory jurisdiction, a 52-week endpoint window, rather than on drug-specific efficacy signal, which means the number reflects trial structure more than the molecule's demonstrated biology.
Why the gap matters
Huadong has a completion rate of 100% across seven prior global trials and runs 45 total trials in its broader portfolio, so operational execution is not the open question. The open question is disclosure. A Phase 3 trial reaching Completed status without a topline readout, safety summary, or stated regulatory plan leaves investors unable to judge whether the China result tracked the US precedent or diverged from it. Roflumilast's PDE4 mechanism carries no first-in-class distinction here; the competitive frame is defined by Amgen's apremilast and Otsuka's difamilast as direct PDE4 comparators, alongside JAK1, TYK2, and IL-23/IL-17A programs from Takeda, Bristol-Myers Squibb, and AbbVie that compete for the same patient population under different mechanisms.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.